Back to today’s briefing

Story perspectives

FDA Approves Ibtrozi: Breakthrough for Lung Cancer Patients

6/12/2025

41 9

Summary

Story summary

The FDA has greenlit Nuvation Bio Inc.'s Taletrectinib, now known as Ibtrozi, to combat ROS1-positive non-small cell lung cancer, which impacts 1-2% of lung cancer patients. Remarkably, clinical trials revealed that 85-90% of untreated patients saw their tumors shrink, as the drug effectively targets and inhibits the rogue ROS1 protein, stalling cancer progression.

1 of 1

Story summary

The FDA has greenlit Nuvation Bio Inc.'s Taletrectinib, now known as Ibtrozi, to combat ROS1-positive non-small cell lung cancer, which impacts 1-2% of lung cancer patients. Remarkably, clinical trials revealed that 85-90% of untreated patients saw their tumors shrink, as the drug effectively targets and inhibits the rogue ROS1 protein, stalling cancer progression.